M

Multiply Labs

Robotic biomanufacturing infrastructure for cell therapies

Vice President Software Engineering - Robotics & System

Full-Time
$250k - $320k/yr+ Equity
Expert
San Francisco, CA, USA
In PersonTravel up to 5-10% domestically and internationally.
H1B Sponsorship Available

About the job

Requirements
  • Lead Technical Evolution: Build upon our existing software architecture across Robotics (motion planning, kinematics) and Platform (cloud, scheduling, distributed systems). You will translate ambiguity into clear technical plans and scope minimum viable solutions, ensuring the stack remains robust and maintainable as system complexity increases.
  • Innovation Transfer: Partner with our R&D Software team to transition frontier robotic advancements into commercial production. You will bridge the gap between research and production, ensuring that experimental features are rigorously integrated and stabilized before they reach our deployed clusters.
  • Standards & Excellence: Evaluate our current Software Development Lifecycle and provide strategic feedback to close process gaps. You will guide the team in adopting and refining industry standards for code reviews, release management, versioning strategies, and technical documentation.
  • Reliability & Testing Strategy: Champion a strategy for mission-critical reliability. You will oversee the maturation of our testing frameworks—building on our existing simulation and integration tests—and guide the strategic ramp-up of Hardware-in-the-Loop (HIL) testing.
  • Product Alignment: Work alongside Hardware, Product, and Biology leadership to ensure software roadmaps align with physical constraints. You will help translate complex biological protocols and physical constraints into realistic software roadmaps.
  • Customer Focus & Technical Strategy: Occasionally meet with customers to understand their needs and ensure our engineering efforts are solving the right problems. You will use this context to define the strategy for balancing new feature delivery with the reduction of technical debt, ensuring sustainable velocity.
  • Scale the Organization: You will prepare the engineering team for a critical phase of growth—moving from a single Process Development (PD) unit to a fleet operating in both PD and regulated GMP environments. You understand the operational rigor required to support commercial GMP systems without stifling the agility needed for ongoing development.
  • Mentorship & Career Guidance: You will take an active role in the professional development of your team. You will provide coaching, define clear career pathways, and ensure that engineers have the mentorship they need to evolve into technical leaders and effective managers.
  • Team Culture & Values: Champion our existing culture of positivity and collaboration, ensuring these values persist as the organization scales. You will foster an environment of high trust and personal ownership, where intellectual honesty is valued over ego.
Responsibilities
  • Lead Technical Evolution across Robotics (motion planning, kinematics) and Platform (cloud, scheduling, distributed systems). Translate ambiguity into clear technical plans and scope minimum viable solutions, ensuring the stack remains robust and maintainable as system complexity increases.
  • Partner with R&D Software to transfer frontier robotic advancements into commercial production and ensure experimental features are integrated and stabilized before deployment.
  • Evaluate and improve our Software Development Lifecycle, guiding the team in adopting industry standards for code reviews, release management, versioning strategies, and technical documentation.
  • Oversee the maturation of testing frameworks and guide ramp-up of Hardware-in-the-Loop testing to ensure mission-critical reliability.
  • Collaborate with Hardware, Product, and Biology leadership to align software roadmaps with physical constraints and translate biological protocols into realistic software roadmaps.
  • Engage with customers to understand needs and shape technical strategy, balancing feature delivery with reduction of technical debt to sustain velocity.
  • Prepare the engineering team for growth from a single PD unit to a fleet operating in PD and GMP environments, ensuring operational rigor without sacrificing agility.
  • Provide mentorship and career guidance, coaching engineers and defining clear career pathways to develop technical leaders and effective managers.
  • Foster a culture of positivity, collaboration, high trust, and intellectual honesty as the team scales.

About the company

Multiply Labs builds robotic biomanufacturing infrastructure for cell and gene therapies and advanced biologics. Its modular Cluster automates workflows by integrating existing GMP instruments in a closed system and learning processes through imitation learning rather than full process transfer. Digital QC software monitors real-time sensors and generates 21 CFR Part 11–compliant electronic batch records. The company partners with pharma and research institutions to expand scalable, compliant manufacturing capacity and accelerate commercial-scale product development.

Company Size

51-200

Company Stage

Series A

Total Funding

$23M

Headquarters

San Francisco, California

Founded

2016

Get referred to Multiply Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 raised $75 million to expand capacity and accelerate commercial-scale product development.
  • May 14, 2024 Retro Biosciences deal became Multiply Labs' first commercial robotic system sale.
  • January 27, 2026 AstraZeneca and existing partners expand credibility with top-tier pharma buyers.

What critics are saying

  • Cellares, Thermo Fisher, Cytiva, and Sartorius already crowd the same automation budget.
  • May 2026 Italy subsidiary still lacks disclosed capacity plans, timelines, and customer commitments.
  • If AstraZeneca and Retro pilots stall, Multiply Labs stays a capital-intensive demo vendor.

What makes Multiply Labs unique

  • Multiply Labs' January 27, 2026 AstraZeneca collaboration validates GMP-ready robotic cell-therapy automation.
  • May 27, 2026 Italy subsidiary and Enrico Racca show manufacturing-first scaling discipline.
  • September 2026 Series B investors include AstraZeneca Ventures, Legend Biotech, and Founders Fund.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Work from home option

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -2%

2 year growth

↑ 0%
Tracxn
Apr 6th, 2026
Multiply Labs - Funding & investors.

Multiply Labs - Funding & investors. Last updated: April 6, 2026 Multiply Labs' funding rounds. Multiply Labs has raised a total of $41.3M over 7 funding rounds: 3 Seed and 4 Early-Stage round s. Multiply Labs' largest funding round so far was a Series A round for $***** in Apr 2021. Here is the list of all funding rounds of Multiply Labs: | Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors | | Apr 21, 2023 | 2041367 | Series A | 3319109 | 9135293 | 3099539 | 4086360 | | Apr 14, 2021 | 2657263 | Series A | 5925816 | 4466755 | 6608485 | Lux Capital & 3 more | | Oct 27, 2018 | 9572761 | Series A | 4644887 | 9212511 | 8077938 | 2014680 | | May 11, 2017 | 4797781 | Series A | 3875885 | 9861974 | 3348546 | Graph Ventures & 5 more | | 2016 | 3338 | Seed | 8966 | 6394 | MIT Sandbox Innovation Fund Program | 1984 | | Aug 22, 2016 | 6270815 | 275706 | 1251781 | 3745093 | 8161543 | 4582795 | | Aug 20, 2016 | 6353672 | 624806 | 7882936 | 5171611 | 9475670 | 8336843 | Multiply Labs' investors. Multiply Labs has total 24 investor s, 24 are institutional investors including Y Combinator and 23 others. Here is the list of institutional investors of Multiply Labs: * Lux Capital, located in Menlo Park (United States), made their first investment in Multiply Labs on Apr 14, 2021 in its Series A round. * Graph Ventures, located in San Francisco (United States), made their first investment in Multiply Labs on May 11, 2017 in its Series A round. * MIT Sandbox Innovation Fund Program, located in Cambridge (United States), made their first investment in Multiply Labs on 2016 in its Seed round. Are you a Founder? FAQs about Multiply Labs' funding and investors. Multiply Labs has raised a total of $41.3M over 7 rounds. Multiply Labs' largest funding round was a Series A round held on Apr 14, 2021 for $*****. * 4 Early-Stage rounds * 3 Seed rounds Multiply Labs has a total of 24 investors, all of them are Institutional investors. Explore latest companies that raised funding recently * Budderfly - Shelton based, raised a funding of $100M in Conventional Debt round held on Jun 23, 2025. * Vizsla Silver - Vancouver based, raised a funding of $100M in Post IPO round held on Jun 23, 2025. * PhysicsX - London based, raised a funding of $135M in Series B round held on Jun 23, 2025. * Techarena - raised a funding of $1.24M in Seed round held on Jun 23, 2025. * Tattle - New York City based, raised a funding of $1.5M in Venture Debt round held on Jun 23, 2025.

Business Wire
Jan 27th, 2026
Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing with robotics

Multiply Labs has announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration will focus on end-to-end robotic automation of industry-standard instruments using Multiply Labs' biomanufacturing platform. The San Francisco-based robotics company develops autonomous manufacturing technology for advanced therapies. Its newest systems use four robotic arms operating in parallel to run cell therapy manufacturing instruments, aiming to maximise output whilst minimising process modifications. "Cell therapies are among the most promising, yet complex medicines being developed today," said Fred Parietti, CEO of Multiply Labs. "Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale." The collaboration seeks to enable scalable, high-throughput manufacturing whilst maintaining quality and regulatory standards for clinical and commercial use.

StockTitan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).

RegMedNet
May 23rd, 2024
Cell therapy weekly: Funding supports remyelination therapy for multiple sclerosis

Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.

Business Wire
May 21st, 2024
Portal Biotechnologies And Multiply Labs Announce Partnership To Automate Cell Engineering In Cell Therapy Manufacturing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function